Targeted kutumira kwezvinodhaka kwezvipatara zvekenza

Target Ichi chinyorwa chinoongorora nzira dzakasiyana siyana dzinoshandiswa mukati Targeted kutumira kwezvinodhaka kwezvipatara zvekenza, kuongorora maitiro avo, zvakanakira, uye nematambudziko. Isu tinonamira mumienzaniso chaiyo uye funga nezveramangwana rei iri rakakosha munda mu oncology.

Kunzwisisa kwakanangidzirwa kuendesa zvinodhaka

Chii chinonongerwa zvinodhaka zvinodhaka?

Kusiyana nechembere yemakemotherapy, inogovera zvinodhaka mumuviri wese, Targeted kutumira kwezvinodhaka kwezvipatara zvekenza inotarisa pakuendesa mairesi ezviratidziro zvakananga kumasokisi cancer. Iyi nzira inoderedza kukuvadza kune hutano hwehutano, zvichitungamira kune mashoma mhedzisiro uye zvakavandudza mabiko ekurapa. Nzira dzakasiyana siyana dzinosiyana siyana dzinoshandirwa kuzadzisa izvi zvakarongedzwa kuburitsa, imwe neimwe ine hunhu hwakasiyana uye zvikumbiro.

Michina yeanonongedzerwa zvinodhaka

Manhamba akati wandei anofambisa Targeted kutumira kwezvinodhaka kwezvipatara zvekenza. Izvi zvinosanganisira:

• Antibody-zvinodhaka conjugates (adcs): Vantihodhi vanonyatsosunga mashekeri echicancer, vakatakura zvinodhaka zvakananga kune bundu racho.
• Liposomal Dhirowa Dhirowa: Zvinodhaka zvakagadzirirwa mukati meLiposomes, izvo zvinobva zvaanangwa kune cancer cell uchishandisa chaiyo ligands kana antibodies.
• NANOPARLECLE DUBS DUBS: Nuoparticles inogona kugadzirwa kutakura zvinodhaka kune bundu saiti, zvingangoita kushandisa iyo yekuvandudza mukana wekuvandudza uye nekuchengetwa (EPR) maitiro.
• Inotarisirwa Nanoparticles: Aya anoshandisa nzvimbo yekugadziridzwa senge ligands kana antibodies ekunyepedzera kunongedzo kune tumor masero.

Mhando dzeVanonongedzerwa Dhivha Dhivha Systems

Antibody-zvinodhaka conjugates (adcs)

Adcs muenzaniso wakakurumbira we Targeted kutumira kwezvinodhaka kwezvipatara zvekenza. Vanosanganisa chokwadi che monoclonal antibodies ne potency yezvinodhaka zveCyttory. Iyi nzira inosimudzira kushanda kwekubudirira nekuburitsa zvakananga zvinodhaka kune cancer masero, uku uchiramba uine hutano. Semuenzaniso, trastuzumab Emtansine (Kadcyla) idc inoshandiswa kurapa kenza yake yechipfuva.¹

Kuunza liposomal zvinodhaka

Rondedzero inokweretesa mushonga, ichivadzivirira kubva mukusvibiswa uye kuwedzera nguva yayo kutenderera muropa. Iyi yakavandudzwa pharmacokinetics inobvumira kune yakanangidzirwa yekutumira kune tumor masero kuburikidza neyakainongedza ligands kana Passive kuunganidzwa kuburikidza neEPR ECTE. Doxorubicin Losomes (i., doxil) ndiwo muenzaniso wakabvumidzwa muenzaniso.²

Zvakanakira uye Matambudziko eVanonongedzerwa Dhirowa Dhirowa

Ramangwana reVanonongedzerwa Dhivha Dish Dish Dish Kutambisa Kenani

Tsvagiridzo inoenderera ichinatsa uye kuwedzera mukana we Targeted kutumira kwezvinodhaka kwezvipatara zvekenza. Kufambira mberi muNanotechnology, genomics, uye kufungidzira kuri kutungamira kukudziridzwa kwehurongwa hwakawanda uye hunoshanda. Kubatanidzwa kwemishonga yakasarudzika uye kushandiswa kwekusanganisa kurapa kuri kuitawo nzira kune yakagadziridzwa zvibodzwa mu cancer kurapwa kwekara cancer. Kuti uwane rumwe ruzivo nezvekanza yekaramu yepamberi uye research, shanyira iyo Shandong baofa cancer researching Institute.

¹ FDA. (N.d.). Kadyla (Trastuzumab Emtansine). Kudzoserwa kubva [https://www.fdags.gov/inturmationdrugbs/quvedrugbs/ucrevation

² FDA. (N.d.). Doxil (doxorubicin hcl liposomal jekiseni). Dzinotorwa kubva [https://www.c.c.gov/cders/cders: